The Allspring Large Cap Core Fund generated a total return of -5.78% for the quarter vs. the benchmark S&P 500 Index's -4.27% ...

REGN stock has seen an impact that was slightly ... as evident in HQ Portfolio performance metrics. The views and opinions expressed herein are the views and opinions of the author and do not ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

The CRISP Mutual Funds Scorecard, unveiled by Share.Market, evaluates mutual funds from April 2020 to March 2025, offering ...

Tech Stock News IPO News Artificial Intelligence (AI) ... REGN Regeneron Pharmaceuticals, Inc. ... Performance Risk EPS Revisions Income Statement (TTM) ...

Regeneron Pharmaceuticals saw a downgrade from Wells Fargo, slicing its stock rating from "overweight" to "equal weight" and ...

Regeneron Pharmaceuticals just hit a new 52-week low after UBS dropped its price target and slapped on a neutral rating.

Get the latest news on Regeneron Pharmaceuticals stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Regeneron Pharmaceuticals performance ...

Regeneron Pharmaceuticals REGN +2.20% Get Free Report has outperformed the market over the past 15 years by 9.69% on an ...

We note that REGN has had a rough time so far this year. The stock got hammered last week after REGN and partner Sanofi SNY reported results from two late-stage studies, AERIFY-1 and AERIFY-2 ...